Comparison of Rp-Hplc Columns Used For Determination of Nucleoside Metabolic Patterns in Urine of Cancer Patients

Waszczuk-Jankowska, Małgorzata; Markuszewski, Michał J.; Markuszewski, Marcin; Kaliszan, Roman

doi:10.4155/bio.12.89

Cited by 16 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The excretion of ribonucleosides is not affected by age and diet [2]. But elevated levels of ribonucleosides were observed in patients with physical illness, such as urogenital cancer [3,4], hepatocellular carcinoma [5,6], breast cancer [7], acquired immunodeficiency diseases (AIDS) [8,9] and severe combined immunodeficiency diseases (SCID) [10]. Therefore, the levels of urinary ribonucleosides can be considered as a signal of disease status, especially as potential biomarkers for cancer diagnosis.…”

Section: Introductionmentioning

confidence: 99%

A novel method of liquid chromatography–tandem mass spectrometry combined with chemical derivatization for the determination of ribonucleosides in urine

Jin

Zhi

et al. 2015

Analytica Chimica Acta

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A novel method of liquid chromatography–tandem mass spectrometry combined with chemical derivatization for the determination of ribonucleosides in urine

Jin

Zhi

et al. 2015

Analytica Chimica Acta

View full text Add to dashboard Cite

“…Based on the DEDC algorithm, the optimal gene set was nucleoside metabolic process (GO\GO:0009116) with Δ * G =18.681 and 24 HDE-HDC partitions in total. Nucleoside metabolic process refers to chemical reactions and pathways involving a nucleoside, a nucleobase linked to either β-D-ribofuranose (a ribonucleoside) or 2-deoxy-β-Dribofuranose (a deoxyribonucleoside), for example, uridine, inosine, guanosine, adenosine, cytidine and deoxyadenosine, deoxyguanosine, deoxycytidine and thymidine (44). Metabolic incorporation of azido nucleoside analogues into living cells enables sensitive detection of DNa replication through copper (I)-catalyzed azide-alkyne cycloaddition and strain-promoted azide-alkyne cycloaddition (45), whereas the altered DNa replications often lead to disease or even cancer.…”

Section: Discussionmentioning

confidence: 99%

Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm

Dong

Zhou

et al. 2016

Oncology Reports

View full text Add to dashboard Cite

The objective of this study was to identify the optimal gene and gene set for hepatocellular carcinoma (HCC) utilizing differential expression and differential co-expression (DEDC) algorithm. The DEDC algorithm consisted of four parts: calculating differential expression (DE) by absolute t-value in t-statistics; computing differential co-expression (DC) based on Z-test; determining optimal thresholds on the basis of Chi-squared (χ2) maximization and the corresponding gene was the optimal gene; and evaluating functional relevance of genes categorized into different partitions to determine the optimal gene set with highest mean minimum functional information (FI) gain (Δ*G). The optimal thresholds divided genes into four partitions, high DE and high DC (HDE-HDC), high DE and low DC (HDE-LDC), low DE and high DC (LDE‑HDC), and low DE and low DC (LDE-LDC). In addition, the optimal gene was validated by conducting reverse transcription-polymerase chain reaction (RT-PCR) assay. The optimal threshold for DC and DE were 1.032 and 1.911, respectively. Using the optimal gene, the genes were divided into four partitions including: HDE-HDC (2,053 genes), HED-LDC (2,822 genes), LDE-HDC (2,622 genes), and LDE-LDC (6,169 genes). The optimal gene was microtubule‑associated protein RP/EB family member 1 (MAPRE1), and RT-PCR assay validated the significant difference between the HCC and normal state. The optimal gene set was nucleoside metabolic process (GO\GO:0009116) with Δ*G = 18.681 and 24 HDE-HDC partitions in total. In conclusion, we successfully investigated the optimal gene, MAPRE1, and gene set, nucleoside metabolic process, which may be potential biomarkers for targeted therapy and provide significant insight for revealing the pathological mechanism underlying HCC.

show abstract

“…Because there are no specific enzymatic systems to incorporate modified nucleosides into the macromolecular nucleic acid, these nucleosides once released cannot be reutilized, nor are they further degraded, but are excreted into the urine . Other studies also have demonstrated that urinary nucleoside excretion is little affected by the diet in humans, and when normalized to urinary creatinine levels, the daily excretion rate of urinary nucleosides is remarkably constant in healthy individuals . Thus, nucleoside detection could be useful in the assessment of human diseases, including cancer.…”

Section: Discussionmentioning

confidence: 99%

Upregulated plasma and urinary levels of nucleosides as biological markers in the diagnosis of primary gallbladder cancer

Jiao

Ying

et al. 2014

J of Separation Science

View full text Add to dashboard Cite

We first detected aberrant nucleoside levels in the plasma, urine, bile, and tissues from cases and controls to explore them as biomarkers in the diagnosis of gallbladder cancer. Reversed-phase high-performance liquid chromatography was used to assess the levels of ten nucleosides in these samples from gallbladder cancer patients, gallstone patients, and healthy controls. Plasma and urine samples were collected from patients with gallbladder cancer (n = 202), patients with gallstones (n = 203), and healthy controls (n = 205); bile and tissue samples were collected from 91 gallbladder cancer patients, 93 gallstone patients; and 90 were donated after cardiac death. Of the ten nucleosides analyzed, eight urinary nucleosides, five plasma nucleosides, three bile nucleosides, and one tissue nucleoside were significantly upregulated in the gallbladder cancer patients compared to control groups (p < 0.05). Among these upregulated nucleosides, the sensitivity, specificity, and accuracy of urinary nucleosides in the diagnosis of gallbladder cancer patients were 89.4, 97.1, and 95.7%, respectively, those of plasma nucleosides were 91.2, 95.6, and 94.2%, respectively, those of bile nucleosides were 95.3, 96.4, and 95.1%, respectively, and those of tissue nucleosides were 86.2, 93.8, and 92.6%, respectively. These results suggest that nucleosides may be as useful as biological markers for gallbladder cancer.

show abstract

Comparison of Rp-Hplc Columns Used For Determination of Nucleoside Metabolic Patterns in Urine of Cancer Patients

Abstract: These results verify the usefulness of the RP-HPLC method to investigate the urinary pattern of normal and modified nucleosides.

Cited by 16 publications

References 13 publications

A novel method of liquid chromatography–tandem mass spectrometry combined with chemical derivatization for the determination of ribonucleosides in urine

A novel method of liquid chromatography–tandem mass spectrometry combined with chemical derivatization for the determination of ribonucleosides in urine

Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm

Upregulated plasma and urinary levels of nucleosides as biological markers in the diagnosis of primary gallbladder cancer

Contact Info

Product

Resources

About